Verdegaal, Els M. E.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 191

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 63

Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines

van den Ende, T. C., Heuts, J. M. M., Gential, G. P. P., Visser, M., van de Graaff, M. J., Ho, N. I., Jiskoot, W., Valentijn, A. R. P. M., Meeuwenoord, N. J., Overkleeft, H. S., et al. (2021) · ChemBioChem

Immunotherapy and Immune ResponsesChemical Synthesis and Analysis

Cited by 9